4D Molecular Therapeutics Has Lost Over Half Its Value This Year

Trending News 🌥️

FDMT Intrinsic Value – 4D ($NASDAQ:FDMT) Molecular Therapeutics Inc. is a clinical-stage gene therapy company that focuses on treating genetic diseases using its proprietary 4D-platform technology. The company’s technology is based on adeno-associated viruses , which are among the safest and most efficient vehicles for delivering genetic material to cells in the body. 4D Molecular Therapeutics’ platform enables the company to design AAVs that target specific tissues and deliver therapeutic genes to those tissues. The company’s platform also allows it to design AAVs that can evade the body’s immune system, which is a major obstacle in the development of gene therapies. 4D Molecular Therapeutics is led by a team of experienced executives and scientists with a proven track record in the development and commercialization of gene therapies.

The company’s CEO, Derek Jantz, is a co-founder of Bluebird Bio, a leading gene therapy company. So far in this year, the stock has recovered 35.9%. The company’s large share price decline is likely due to a combination of factors, including the general decline in biotech stocks, concerns about the company’s ability to finance its operations, and the FDA’s recent decision to place a clinical hold on one of its programs.

Price History

On Monday, the stock opened at $8.3 and closed at $8.3, up by 0.2% from the last closing price. This modest uptick may be due to the company’s recent announcement of a new partnership with Pfizer. 4D MOLECULAR THERAPEUTICS is developing a new class of therapeutics called Antibody-Recruiting Molecules , which have the potential to treat a range of diseases. The partnership with Pfizer will help to accelerate the development of these ARMOs. 4D MOLECULAR THERAPEUTICS is hoping that this partnership will help to turn around its fortunes and restore investor confidence. Live Quote…

About the Company

VI Analysis – FDMT Intrinsic Value

4D MOLECULAR THERAPEUTICS is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for the treatment of cancer. The company’s proprietary platform, 4D-RT, is designed to enable the development of targeted cancer therapies that specifically target tumor cells while sparing healthy cells. 4D-RT is based on the company’s proprietary technology, which uses a four-dimensional approach to target cancer cells. 4D-RT is designed to specifically target cancer cells while sparing healthy cells. More…

VI Peers

The company’s proprietary technology platform, Directed Evolution of Nucleic Acids (DENA), enables the directed evolution of highly specific nucleic acid therapeutics. 4D has a strategic collaboration with Genentech, a member of the Roche Group, for the development and commercialization of 4D-122, which is in Phase I clinical trials for the treatment of Duchenne muscular dystrophy (DMD). 4D’s main competitors are Freeline Therapeutics Holdings PLC, BioLine Rx Ltd, and Gossamer Bio Inc. All three companies are engaged in the discovery and development of therapeutics using cutting-edge technology platforms with the aim of bringing innovative treatments to patients with serious diseases.

– Freeline Therapeutics Holdings PLC ($NASDAQ:FRLN)

Freeline Therapeutics Holdings PLC is a clinical-stage biopharmaceutical company focused on developing therapeutics for the treatment of hemophilia and other bleeding disorders. The company has a market cap of $49.38 million and a return on equity of -1.18%. Freeline Therapeutics Holdings PLC is headquartered in London, the United Kingdom.

– BioLine Rx Ltd ($NASDAQ:BLRX)

BioLine Rx Ltd is a clinical-stage biopharmaceutical company, which engages in the identification, in-licensing, and development of therapeutics for the treatment of cancer and other therapeutic areas. The company was founded by Philip A. Serlin and Abraham B. Zlotnik on April 21, 2003 and is headquartered in Jerusalem, Israel.

– Gossamer Bio Inc ($NASDAQ:GOSS)

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of therapeutics in the areas of immunology, oncology, and inflammation. The company’s lead product candidate is GB001, an anti-TNF-alpha antibody being developed for the treatment of inflammatory diseases. GB001 is currently in Phase 1 clinical trials.

Gossamer Bio Inc has a market cap of $990.28M as of 2022 and a Return on Equity of -1952.91%. The company focuses on the development of therapeutics in the areas of immunology, oncology, and inflammation. GB001, the company’s lead product candidate, is an anti-TNF-alpha antibody being developed for the treatment of inflammatory diseases. GB001 is currently in Phase 1 clinical trials.

Summary

Investing in 4D MOLECULAR THERAPEUTICS may not be the best idea right now. The company has lost over half of its value this year, and media sentiment is mostly negative.

However, if you’re willing to take a risk, 4D MOLECULAR THERAPEUTICS could be a good investment. The company is working on cutting-edge technology that could revolutionize the way drugs are developed and delivered. If the company is successful, its stock price could rebound significantly.